Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H23NO |
Molecular Weight | 269.3813 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCCCCOC1=CC=CC=C1CC2=CC=CC=C2
InChI
InChIKey=QSQQPMHPCBLLGX-UHFFFAOYSA-N
InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3335842Curator's Comment: Description was created based on several sources, including https://drug.mynahcare.com/drugs/genericdetail/bifemelane-Mjg1 | https://www.ncbi.nlm.nih.gov/pubmed/8846747 | https://www.ncbi.nlm.nih.gov/pubmed/8851457 | https://www.ncbi.nlm.nih.gov/pubmed/1794296 | https://www.ncbi.nlm.nih.gov/pubmed/8474231 | https://www.ncbi.nlm.nih.gov/pubmed/1794296 | https://www.ncbi.nlm.nih.gov/pubmed/7490169
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3335842
Curator's Comment: Description was created based on several sources, including https://drug.mynahcare.com/drugs/genericdetail/bifemelane-Mjg1 | https://www.ncbi.nlm.nih.gov/pubmed/8846747 | https://www.ncbi.nlm.nih.gov/pubmed/8851457 | https://www.ncbi.nlm.nih.gov/pubmed/1794296 | https://www.ncbi.nlm.nih.gov/pubmed/8474231 | https://www.ncbi.nlm.nih.gov/pubmed/1794296 | https://www.ncbi.nlm.nih.gov/pubmed/7490169
Bifemelane is a psychotropic drug, was found to inhibit monoamine oxidase (MAO). It inhibited type A MAO (MAO-A) competitively and type B (MAO-B) noncompetitively and it was a more potent inhibitor of MAO-A than of MAO-B. Bifemelane is an antidepressant and cerebral activator that is used in Japan for the treatment of cerebral infarction patients with depressive symptoms, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7205881
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7186825
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3335842 |
4.2 µM [Ki] | ||
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3335842 |
46.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BIFEMELANE Approved UseBIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. |
|||
Primary | BIFEMELANE Approved UseBIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. |
|||
Primary | BIFEMELANE Approved UseBIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. |
|||
Primary | BIFEMELANE Approved UseBIFEMELANE is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms , and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), a new psychotropic drug with antidepressant activity. | 1981 |
|
A novel effect of bifemelane, a nootropic drug, on intracellular Ca2+ levels in rat cerebral astrocytes. | 2006 Feb |
|
Effects of bifemelane on the calcium level and ATP release of the human origin astrocyte clonal cell. | 2006 Sep |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2853846
Bifemelane 10 nM to 1 uM significantly augmented the long-term potentiation in the CA3 region of guinea pig hippocampal slices
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N06AX08
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
||
|
WHO-VATC |
QN06AX08
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB13550
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
DTXSID1045663
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
Z4501GN13G
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
m2480
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1192517
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
5902
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
100000085883
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
BIFEMELANE
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
369
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
2377
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
C031906
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
SUB05827MIG
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
90293-01-9
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
C169812
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | |||
|
47111
Created by
admin on Sat Dec 16 18:00:55 GMT 2023 , Edited by admin on Sat Dec 16 18:00:55 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY